In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device/Diagnostics Quarterly Deal Statistics, Q2 2012

A look at financing, M&A, and alliance activity April–June 2012

Executive Summary

Medical device company financing brought in $977 million, a decrease over Q1’s $1.1 billion. Device acquisition activity was up to $4.6 billion, yet only one deal surpassed the billion-dollar mark. With late-stage financing again leading, diagnostics funding together brought in $336 million, an 11% increase over Q1. For the first time since Q1 2011, the diagnostics M&A dollar total moved up instead of down, with $7 billion in acquisitions and five of the seven transactions topping $100 million.

Advertisement

Related Content

The Renal Denervation Buzz: Separating Fact From Myth; Covidien Buys Maya Medical
Hologic Grabs Gen-Probe
Hologic Increases Bets In Lab Space With $3.7 Bil. Gen-Probe Purchase
Covidien Acquisitions Keeps Buying Spree Alive
Covidien Gains Capnography Market Leader Oridion Via $300 Mil. Acquisition
Covidien Buys superDimension: $300 Mil. Deal Targets Lung Cancer Screening Market
Covidien Gains Ventilators Aimed At Emerging Markets Via Newport Deal
J&J Doubles Down On Orthopedics With Synthes Deal; Takes Lead In Trauma
Stentys' IPO: European Public Markets Opening For Device Companies?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003929

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel